ReproCELL– tag –
-
REPROCELL Offers High-Quality Clinical-Grade iPSC Services with Proprietary StemRNA™ 3rd Gen Technology, Including Reprogramming, Differentiation, and Gene Editing
REPROCELL Japan Overview REPROCELL provides comprehensive, high-quality iPSC reprogramming, differentiation, and gene editing services utilizing its proprietary StemRNA™ 3rd Gen Reprogramming technology. These services encompass efficien... -
REPROCELL Accelerates Clinical-Grade iPSC Manufacturing Scale-Up with StemRNA™ Clinical Platform and AI-Driven StemEdit
REPROCELL Japan Overview REPROCELL is significantly accelerating the scale-up of clinical-grade induced pluripotent stem cell (iPSC) manufacturing by leveraging its proprietary StemRNA™ Clinical iPSC platform and AI-driven StemEdit gene-... -
REPROCELL Accelerates Clinical Production with FDA/EMA/PMDA-Compliant iPSC Manufacturing Platform
REPROCELL Japan Overview REPROCELL has unveiled a robust iPSC manufacturing scale-up strategy aimed at accelerating clinical development and commercialization of iPSC-based therapeutics. Their StemRNA™ Clinical iPSC Platform offers clini... -
REPROCELL Publishes Article on Scaling iPSC Manufacturing: Addressing Challenges from Cell Line Development to Clinical Production
REPROCELL Japan Overview REPROCELL has published an article titled "Scaling iPSC Manufacturing: From Cell Line Development to Clinical Production," focusing on the crucial aspects of industrializing induced pluripotent stem cell (iPSC) t... -
REPROCELL Enables Clinical-Scale iPSC Manufacturing with StemEdit and Bioreactor Technologies
REPROCELL Japan Overview REPROCELL is facilitating a seamless transition from lab-scale iPSC manufacturing to GMP production and clinical application by integrating its StemEdit gene-editing platform with ABLE Biott and BioThrust bioreac... -
AI-Guided 3D Bioreactors Revolutionize iPSC Manufacturing: Scaling Up and Cutting Costs for Accelerated Commercialization
Wiley Analytical Science USA Overview AI-guided 3D bioreactor technology is revolutionizing iPSC manufacturing, enabling reliable, efficient, and scalable production of pluripotent stem cells (PSCs). This innovative platform facilitates ... -
REPROCELL Pioneers Integrated iPSC Manufacturing Platform, Accelerating US Phase III Clinical Programs with AI-Enhanced Gene Editing and GMP Compliance
REPROCELL Japan Overview REPROCELL has launched a comprehensive iPSC manufacturing platform designed to accelerate the clinical development of iPSC-derived therapeutics, notably supporting a US Phase III program. The platform integrates ... -
Japan’s Reprocell and University Announce Joint Development of iPSC Differentiation Protocol, Enhancing Cell Therapy Product Uniformity and Scalability
Reprocell / University Announcement Japan Overview Japanese regenerative medicine company Reprocell, in collaboration with a prominent university research lab, announced the joint development of a novel protocol for high-efficiency diffe... -
REPROCELL Unveils StemEdit Hypoimmune iPSCs with HLA Knockout, Accelerating Development of Off-the-Shelf Cell Therapies
REPROCELL (Blog) Japan Overview REPROCELL has announced the launch of its StemEdit hypoimmune iPSC lines, featuring HLA knockout through high-efficiency genome editing and regulatory-compliant cell lines. This technology aims to mitigate... -
REPROCELL Enhances 3D Cell Culture Product Portfolio with Alvetex® & EZSPHERE™ to Advance Drug Discovery Translational Research
REPROCELL Japan Overview REPROCELL is fortifying its diverse 3D cell culture product lines, including Alvetex® 3D Cell Culture Systems and the Alvetex® Advanced Tissue Bioengineering System, to provide biologically relevant, reproducible...
12